Price movement over the last 24 hours
Agilent Technologies Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Agilent Technologies Inc trades at $128.24 (market cap $37.04B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79. The key difference: Agilent Technologies Inc pays a 0.78% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | FLRN | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $157.20 | $30.86 |
52-Week Low | $110.24 | $30.65 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.78, showing minimal daily movement with a 0.07% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights institutional buying interest amid a higher-for-longer interest rate environment, positioning FLRN as a potential hedge against inflation. The ETF pays consistent dividends, with recent distributions of $0.11 per share.
The outlook for FLRN is cautiously positive, benefiting from its floating-rate structure in a rising rate climate. Key opportunities include inflation protection and steady income, while risks involve interest rate volatility and economic shifts that could impact credit quality. Investor sentiment is mixed, with technical signals leaning bearish but fundamental appeal in current macro conditions.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →